High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Mutations among genes that participate in the canonical Wnt signaling pathway can lead to drastically different skeletal phenotypes, ranging from severe osteoporosis to severe osteosclerosis. Many high-bone-mass (HBM) causing mutations that occur in the LRP5 gene appear to impart the HBM phenotype, in part, by increasing resistance to soluble Wnt signaling inhibitors, including sclerostin. Sost loss-of-function mutant mice (Sost knock-out) and Lrp5 gain-of-function mutant mice (Lrp5 HBM knock-in) have high bone mass. These mutants potentially would be predicted to be phenocopies of one another, because in both cases, the sclerostin–Lrp5 interaction is disrupted. We measured bone mass, size, geometry, architecture, and strength in bones from three different genetic mouse models (Sost knock-out, Lrp5 A214V knock-in, and Lrp5 G171V knock-in) of HBM. We found that all three mouse lines had significantly elevated bone mass in the appendicular skeleton and in the cranium. Sost mutants and Lrp5 A214V mutants were statistically indistinguishable from one another in most endpoints, whereas both were largely different from the Lrp5 G171V mutants. Lrp5 G171V mutants preferentially added bone endocortically, whereas Lrp5 A214V and Sost mutants preferentially added bone periosteally. Cranial thickness and cranial nerve openings were similarly altered in all three HBM models. We also assessed serum serotonin levels as a possible mechanism accounting for the observed changes in bone mass, but no differences in serum serotonin were found in any of the three HBM mouse lines. The skeletal dissimilarities of the Lrp5 G171V mutant to the other mutants suggests that other, non-sclerostin-associated mechanisms might account for the changes in bone mass resulting from this mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic biomechanical measurements of bone: A tutorial
Turner, C. H., & Burr, D. B. (1993) · Bone · doi:10.1016/8756-3282(93)90081-k · Cited by 1,666
Self-citationSclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 1×
“In vitro, the protein product of the SOST gene–sclerostin–has been shown to bind and inhibit wild-type LRP5, but not LRP5 variants that harbor HBMcausing mutations [12–15].”
Little, R. D., Folz, C., Manning, S. P., Swain, P. M., Zhao, S.-C., Eustace, B., Lappe, M. M., Spitzer, L., Zweier, S., Braunschweiger, K., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338450 · Cited by 1,282
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 1×
“A similar high bone mass (HBM) phenotype has been reported among patients with mutations in the SOST gene, or in its distant regulatory elements, which are linked to the sclerosing bone disorders Sclerosteosis and van Buchem's disease [6–8].”
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698 · cited 1×
“A similar high bone mass (HBM) phenotype has been reported among patients with mutations in the SOST gene, or in its distant regulatory elements, which are linked to the sclerosing bone disorders Sclerosteosis and van Buchem's disease [6–8].”
Van Wesenbeeck, L., Cleiren, E., Gram, J., Beals, R. K., Bénichou, O., Scopelliti, D., Key, L., Renton, T., Bartels, C., Gong, Y., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/368277 · Cited by 568 · cited 1×
“Shortly after the discovery of families harboring loss-of-function mutations in LRP5, other investigators identified a series of single amino acid missense mutations in LRP5 in several families that segregated abnormally high bonemass (HBM) in an autosomal dominantmanner [3–5].”
Self-citationLDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction
Weatherbee, S. D., Anderson, K. V., & Niswander, L. A. (2006) · Development · doi:10.1242/dev.02696 · Cited by 351 · cited 1×
“Lrp4 deletion would be expected to result in high bone mass, but Lrp4-null mice (Lrp4−/−) do not survive gestation and preclude such an evaluation [27].”
Cited by
Role of Inactivity in Chronic Diseases: Evolutionary Insight and Pathophysiological Mechanisms
Booth, F. W., Roberts, C. K., Thyfault, J. P., Ruegsegger, G. N., & Toedebusch, R. G. (2017) · Physiological Reviews · doi:10.1152/physrev.00019.2016 · Cited by 696
Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease
Hu, L., Chen, W., Qian, A., & Li, Y.-P. (2024) · Bone Research · doi:10.1038/s41413-024-00342-8 · Cited by 359
Hassan, M. Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J. A. R., Li, Z., Croce, C. M., van Wijnen, A. J., Stein, J. L., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377515 · Cited by 297
Vlashi, R., Zhang, X., Wu, M., & Chen, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.011 · Cited by 165
Metadata
- Authors
- Niziolek, P. J., Farmer, T. L., Cui, Y., Turner, C. H., Warman, M. L., & Robling, A. G.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 49
- Issue
- 5
- Pages
- 1010-1019
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2163737027
- Cited by
- 72
- References
- 8
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.